Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation

Documenti analoghi

• Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization
  di: Philippe Giguère, et al.
  Pubblicazione: (2026)
• Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis
  di: Victoria Murillo, et al.
  Pubblicazione: (2024)
• Phase II trial of posaconazole prophylaxis during anti‐thymocyte globulin treatment for aplastic anaemia and hypoplastic myelodysplastic syndrome
  di: Dong Hyun Kim, et al.
  Pubblicazione: (2024)
• Impact of graft‐versus‐host disease prophylaxis strategies on GvHD ‐free/relapse‐free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score‐matched analysis
  di: Nihar Desai, et al.
  Pubblicazione: (2025)
• Clinical outcomes of modified post‐transplantation cyclophosphamide versus granulocyte colony‐stimulating factor/anti‐thymocyte globulin‐based protocol in alternative donor transplantation for severe aplastic anaemia
  di: Liangliang Wu, et al.
  Pubblicazione: (2025)